SAN CARLOS, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that six abstracts, including one late-breaking abstract highlighting its TIL therapy, will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting from November 8-12, 2017 in National Harbor, Maryland.